Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Rhythm Pharmaceuticals (RYTM) Gross Margin: 2021-2025

Historic Gross Margin for Rhythm Pharmaceuticals (RYTM) over the last 5 years, with Sep 2025 value amounting to 89.28%.

  • Rhythm Pharmaceuticals' Gross Margin rose 79.00% to 89.28% in Q3 2025 from the same period last year, while for Sep 2025 it was 89.40%, marking a year-over-year increase of 79.00%. This contributed to the annual value of 89.73% for FY2024, which is 174.00% up from last year.
  • Latest data reveals that Rhythm Pharmaceuticals reported Gross Margin of 89.28% as of Q3 2025, which was up 0.80% from 88.57% recorded in Q2 2025.
  • Rhythm Pharmaceuticals' Gross Margin's 5-year high stood at 95.83% during Q2 2022, with a 5-year trough of 50.00% in Q2 2021.
  • In the last 3 years, Rhythm Pharmaceuticals' Gross Margin had a median value of 88.85% in 2025 and averaged 88.83%.
  • Its Gross Margin has fluctuated over the past 5 years, first soared by 4,583bps in 2022, then plummeted by 746bps in 2023.
  • Quarterly analysis of 5 years shows Rhythm Pharmaceuticals' Gross Margin stood at 87.01% in 2021, then surged by 129bps to 88.30% in 2022, then tumbled by 165bps to 86.66% in 2023, then spiked by 429bps to 90.95% in 2024, then surged by 79bps to 89.28% in 2025.
  • Its Gross Margin was 89.28% in Q3 2025, compared to 88.57% in Q2 2025 and 88.85% in Q1 2025.